Welldoc, Astellas strike commercialization, development deal bring to BlueStar to East Asia
Summary
Welldoc is tapping Astellas Pharma to assist Japanese and Asian commercialization efforts for the former’s digital therapeutic for patients with diabetes, the companies announced yesterday. To kick off the deal, Astellas is making an upfront $15 million payment to Welldoc, which will allow the pharma to jointly develop and commercialize the BlueStar product in the region. “Under our Strategic Plan 2018, Astellas is committed to Developing Rx+TM programs, which aim to create new, clinically relevant healthcare solutions (Rx+TM) that combine expertise gained from its prescription drug (Rx) business with technology and knowledge from different fields. Our alliance with Welldoc, a pioneer in the digital therapeutics field, is part of this commitment,” Naoki Okamura, representative director corporate EVP, chief strategy officer and CFO for Astellas, said in a statement. But things haven’t always been rosy between digital health startups and pharmas as of late, as just last month came word that Pear Therapeutics and and Novartis subsidiary Sandoz were winding down their commercialization partnership for reSET and reSET-O.
Classifications
AskAI Classifications
LabelsLinked Companies
